---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-26-000048"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2026-08-13T20:05:58+00:00"
generated_at: "2026-08-13T20:08:06.695722+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Serina reports Q2 net loss of $8.9M, advances SER-252 trial ahead of schedule

## Summary
- Net loss attributable to common shareholders was $8.9M, or $(0.55) per share, vs $6.6M loss ($(0.66)) in Q2 2025.
- Operating expenses rose to $6.8M from $5.7M; R&D $3.8M, G&A $3.0M; cash $23.0M at June 30, 2026.
- Completed enrollment/dosing of all 8 patients in Cohort 1 of SER-252 Phase 1b registrational study in July 2026, ahead of Q3 2026 guidance.
- Top-line data from single-ascending-dose arm targeted for H1 2027; partnered with Gannet BioChem for process development and manufacturing.
- Appointed Farrell Simon, Pharm.D., to Board of Directors and Audit/Compensation Committees in July 2026.

## SEC filing metadata
- accession: 0001708599-26-000048
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2026-08-13T20:05:58+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/0001708599-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/ser-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-26-000048
- JSON: https://secwatch.observer/filing/0001708599-26-000048.json
- Plain text: https://secwatch.observer/filing/0001708599-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.